Indore, India
GENOMICS • ANTIMICROBIAL RESISTANCE • AI • PRECISION HEALTHCARE
Ras Al Khaimah (RAK), UAE
From Genes to Intelligence. From Data to Better Decisions.
Understand microbiome findings, antimicrobial resistance information, health insights and practical prevention guidance in simple language.
Integrate laboratory, genomic and clinical information into an organized decision-support view for clinical review.
Support advanced infectious disease research using bioinformatics, genomics, AI and machine-learning approaches.
Explore aggregated AMR trends, surveillance indicators and population-level intelligence with appropriate governance.
A major global healthcare challenge
Historically cited annual AMR-associated mortality estimates
Frequently cited future AMR burden projection requiring continued review
Increasing resistance can reduce treatment options
Integrating data for research and decision support
AI-PID is designed as a collaborative precision infectious disease intelligence platform integrating microbiology, antimicrobial resistance, microbiome analysis, resistome profiling, genomics, NGS, bioinformatics, artificial intelligence and machine learning.
The platform vision is to bring multiple complex data sources into one structured digital environment. AI-PID can support research workflows, laboratory data integration, patient-friendly reporting, clinician-oriented summaries and population-level surveillance.
The long-term research objective is to develop and validate intelligent models that can identify meaningful patterns across microbiological, genomic and clinical datasets.
AI-PID is intended to support structured analysis of antimicrobial resistance data, resistance patterns and emerging microbial threats.
Organize antimicrobial susceptibility and resistance information from laboratory and genomic data for research and clinical review.
Explore temporal and population-level changes in resistance patterns and potential emerging trends.
Develop and evaluate algorithms for identifying unusual patterns that may require expert investigation or public-health review.
The platform can organize microbiome sequencing results into understandable profiles and research-oriented microbial ecosystem analyses.
Explore diversity, abundance and distribution of microorganisms across available sample datasets.
Translate complex microbiome measurements into understandable explanatory summaries while preserving scientific context.
Research machine-learning approaches for discovering relationships and patterns across large microbiome datasets.
Resistome analysis investigates genetic elements associated with antimicrobial resistance within microbial and metagenomic datasets.
Support identification and structured annotation of antimicrobial resistance genes using validated bioinformatics workflows and databases.
Explore relationships between organisms, genes, resistance mechanisms and available metadata.
Compare resistance patterns across cohorts, locations, time periods and research datasets.
AI-PID aims to research and develop transparent, validated machine-learning models for complex infectious disease datasets.
Identify complex relationships across microbiological, genomic and structured clinical research data.
Develop research models that can estimate outcomes or classifications subject to validation, uncertainty reporting and clinical governance.
Prioritize model interpretability, feature transparency and performance evaluation rather than unexplained black-box outputs.
A proposed end-to-end workflow from data collection through analysis, validation and reporting.
Authorized laboratory, clinical and research data are entered through controlled workflows.
Data quality, completeness and analytical suitability are assessed.
Sequencing and microbial datasets are processed using defined analytical pipelines.
Validated analytical models generate research or decision-support outputs.
Role-specific reports are generated for patients, clinicians, researchers or authorized public-health users.
AI-PID can present different levels of information depending on the intended authorized user.
A simplified report designed to help patients understand available findings without replacing medical consultation.
A structured clinical decision-support summary designed for professional review.
Aggregated and appropriately governed surveillance intelligence for authorized population-level analysis.
A future research direction for AI-PID is the development of privacy-protected population-level infectious disease intelligence systems.
Potential research applications could include aggregated surveillance, laboratory-confirmed trend monitoring and early detection of unusual patterns among authorized datasets. Any implementation would require regulatory approval, privacy protection and public-health governance.
Authorized public-health users could explore aggregated resistance trends, geographic variation, temporal patterns and emerging threats to support evidence-based planning and surveillance.
AI-PID is envisioned as a collaborative research platform bringing together healthcare professionals, bioinformaticians, data scientists and researchers.
Study infectious disease data and real-world evidence under appropriate ethics and governance frameworks.
Develop reproducible workflows for microbial genomics, metagenomics and antimicrobial resistance analysis.
Develop, benchmark and validate machine-learning models using robust evaluation frameworks.
AI-PID is intended to bring together expertise from healthcare, microbiology, bioinformatics, genomics and artificial intelligence.
Bioinformatics & AI Research
Genomics, NGS, bioinformatics, machine learning, healthcare data science and computational biology.Clinical Collaboration
Clinical expertise, healthcare implementation and collaborative validation pathways.Future AI-PID Collaboration
Clinicians, microbiologists, researchers, bioinformaticians, data scientists and AI specialists.This section will showcase AI-PID research publications, conference presentations, datasets, protocols and collaborative scientific outputs as they are developed and published.
Future peer-reviewed publications describing the methodology, validation and scientific findings of the AI-PID project.
Research resources and datasets that can be shared in accordance with ethics, consent, privacy and institutional approvals.
A platform to document validated innovations, collaborations and research milestones.
For research collaboration, clinical innovation, technology development or institutional partnerships.
A collaborative initiative involving Eminent Biosciences and RAK Hospital, focused on research and innovation in precision infectious diseases.